Home

The content presented here was prepared by independent authors under the editorial supervision of Creative Educational Concepts, Inc. and does not represent a publication of the American Society of Clinical Oncology. These materials are not sanctioned by ASCO and do not constitute an official part of that meeting.

Target Audience
This activity has been designed to meet the educational needs of physicians, pharmacists, and advance practice nurses who are involved in the treatment and management of patients with glioblastoma multiforme.

Statement of Need
Cancer is the second leading cause of death in the United States, and places a significant burden on the healthcare community. In an attempt to prevent cancer-related deaths, the armamentarium of available treatment options continues to expand, particularly in the area of pharmacologic treatment. It is essential that the healthcare community remains up to date with the latest data on advancements in pharmacotherapy. The results of multiple and varied cancer research studies are presented each year at the American Society of Clinical Oncology (ASCO) annual meeting. This activity will enable participants to receive information that was presented at the much larger society meeting, in a smaller forum. Patterns of practice have the potential to change based on new data, and the accessibility to this overview allows participants to remain informed.

Educational Objectives
Upon completion of this activity, participants should be better able to:

• Apply advances in scientific and translational research in the care of their patients.
• Discuss clinical trial data and safety profile of targeting the angiogenesis pathway
• Assess the clinical impact of emerging strategies targeting angiogenesis on survival and quality of life for glioblastoma patients.

Faculty Information

David A. Reardon, MD Associate Professor Associate Deputy Director The Preston Robert Tisch Brain Tumor Center at Duke Duke University Medical Center

Biography
Dr. Reardon completed his residency at Johns Hopkins Hospital in Baltimore, MD, and his fellowship at the University of Michigan in Ann Arbor, MI. Dr. Reardon works with the team to design and implement clinical trials using innovative therapeutic agents to improve the cure rates of patients with brain and spinal tumors. In addition to trials implementing new chemotherapy regimens, he focuses on the use of novel "tumor-targeting" therapeutics including anti-angiogenesis agents for primary brain tumor patients. He also oversees the use of radio labeled monoclonal antibody trials for patients with high-grade gliomas.

Dr. Reardon is the recipient of the 2007 R. Wayne Rundles Award for Excellence in Cancer Research. The R. Wayne Rundles Award for Excellence in Cancer Research is presented annually to a Duke investigator whose research has made an important contribution to the detection, treatment, or prevention of cancer. The award pays tribute to Wayne Rundles, MD, a pioneer in chemotherapy and leader in the development of national cancer programs and policies. Rundles served as a model to physician scientists beginning their careers in the field of cancer.

Instructions
To receive a statement of credit, you must:

• Review the full content of the activity and reflect upon its teachings
• Complete the questions and evaluation at the end of the activity

Accreditation

Medicine

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been assigned ACPE# 245-000-08-017-H01-P will award 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming. Statements of credit will be issued automatically online.

Nursing
CEC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. CEC provides this activity for 1.0 contact hour.

Fee
This activity is complimentary.

Disclosure Declaration
It is the policy of CEC ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems. Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC of any product or manufacturer identified.

Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

Supporting Organization
This activity is supported by an educational grant from Genentech BioOncology.